



FOR IMMEDIATE RELEASE:  
April 2008

FOR MORE INFORMATION:  
Mike Eldred, President  
Dechra US Operations  
913-327-0015  
mike.eldred@dechra.com

## **Dechra Appointed Exclusive Distributor of Oxyglobin® Oxygen Therapeutic For Veterinary Use in the United States**

*OVERLAND PARK, Kansas* — Dechra Veterinary Products (Dechra) has secured exclusive marketing and distribution rights in the United States for Oxyglobin® Solution [hemoglobin glutamer-200 (bovine)] from Biopure Corporation (Nasdaq: BPUR), Cambridge, Mass.

Oxyglobin is approved by the FDA for veterinary use and is indicated for the treatment of canine anemia. Anemia is a potentially life-threatening condition affecting millions of dogs annually. It can be caused by a number of medical conditions, including blood loss due to trauma, surgery, parasitic disease, gastrointestinal bleeding, and rodenticide toxicity. Oxyglobin has been used to successfully treat anemia related to secondary chronic conditions, such as liver and kidney disease as well as other diseases that can cause a decrease in red blood cells.

“Oxyglobin is a great addition to our rapidly growing portfolio of FDA-approved pharmaceuticals for the companion animal health market in the United States,” said Mike Eldred, President of Dechra U.S. Operations, Overland Park, Kan. “The importance of this oxygen-carrying product to the veterinarian cannot be underestimated. Our exclusive sales, distribution and marketing rights for Oxyglobin will assure Biopure a full reach in this large segment of the animal health business.”

“We look forward to mutual success with Dechra U.S. to have Oxyglobin reach its market potential,” stated Barry Scott, Vice President, Business Development, Biopure Corporation.

### **Provides Immediate Relief from Anemia**

Anemia, the shortage of red blood cells, is the result of numerous medical conditions or diseases. Oxyglobin is the only FDA-approved treatment available that provides immediate relief from clinical signs of anemia in dogs.

Oxyglobin is used as an oxygen-carrying fluid therapy for canine patients and as an alternative to red blood cell transfusion, which can save valuable minutes in an emergency situation. Oxyglobin does not require recipient blood typing, testing or cross-matching prior to use, and is stable at room temperature for three years from the date of manufacture.

A clinical trial of 64 anemic dogs showed a 95 percent efficacy rate as defined by increase in plasma hemoglobin and improvement in physical condition in those treated with Oxyglobin compared with 32 percent in the control group, which received cage rest. Oxyglobin-treated dogs also had significantly increased plasma hemoglobin concentration and a significantly improved physical condition as measured by heart rate, attitude and physical activity compared to pre-treatment.

### **Availability**

Dechra will market Oxyglobin in 60 mL single dose and 125 mL single dose infusion bags. The product must be stored in its sealed foil overlap to protect the hemoglobin from oxidation to methemoglobin, the inactive form of hemoglobin. Recommended storage is at room temperature to avoid accidental freezing. Because of denaturation of protein upon thawing, Oxyglobin cannot be frozen.

To order, veterinarians can contact Dechra at (866) 933-2472. Once an account is established, Oxyglobin is shipped directly to the licensed veterinarian.

Under the terms of the agreement with Dechra, Biopure Corporation will continue to manufacture Oxyglobin at its facilities in Cambridge, Mass. NADA #141-067, approved by the FDA. Oxyglobin® Solution and its method of preparation are covered by one or more of the following United States Patents: No. 5,084,558; No. 5,618, 919; No. 5,691,452 and No. 5,296,465. Oxyglobin is a registered trademark of Biopure Corporation.

For more information about Oxyglobin, see [www.oxyglobin.com](http://www.oxyglobin.com) or [www.dechra-us.com](http://www.dechra-us.com).

### **About Dechra**

Dechra has been successful at developing its presence in the U.S. veterinary market by adding FDA-approved products to its portfolio and developing the company's ability to meet the needs of the expanding companion animal market. Sales and marketing operations are located in Overland Park, Kan.

Dechra markets a range of products in the United States, including Animax®, Cat Lax®, Muricin®, Puralube®, Vetromax®, Vetrachloracin®, Vetrobiotic®, Vetrogen®, and Vetropolycin®. The company is also pursuing FDA approval for Vetoryl® (trilostane), Felimazole® (methimazole) and Equidone® (domperidone). For further information, contact Mike Eldred, President U.S. Operations at (913) 327-0015 or visit [www.dechra-us.com](http://www.dechra-us.com).

**About Dechra Pharmaceuticals PLC (LSE Ticker: DPH)**

Dechra Veterinary Products is a division of Dechra Pharmaceuticals PLC, a UK Stock Exchange Listed Company deriving its income from the international animal healthcare markets. Dechra Pharmaceuticals PLC operates under two divisions: Pharmaceuticals and Services. Both divisions are focused on the veterinary market with a key area of specialization in companion animal products. The group employs more than 750 people at 17 locations throughout Europe and the United States. More information about Dechra Pharmaceuticals PLC can be found at [www.dechra.com](http://www.dechra.com).

**About Biopure Corporation (Nasdaq: BPUR)**

Biopure Corporation is located in Cambridge, Mass. The company develops, manufactures and markets pharmaceuticals called oxygen therapeutics that are administered intravenously to deliver oxygen to the body's tissues. In addition to Oxyglobin® Solution [hemoglobin glutamer-200 (bovine)] for the veterinary market, the company produces Hemopure® [hemoglobin glutamer-250 (bovine)], approved in South Africa for the treatment of human surgical patients who are acutely anemic.

# # #